Longevity Briefing
A curated daily readout of the science, companies, capital flows, and policy moves shaping longevity.
KEANAISSANCE convenes a tightly curated group of founders, investors, clinicians, and operators in a setting designed to accelerate execution in the longevity economy. By removing the audience layer and focusing on decision-makers with direct agency, it creates an environment where capital, science, and delivery can align more quickly. The result is not just discussion, but a higher probability of real partnerships, capital deployment, and tangible progress.
Trending Now
Based on last 48h engagement
More from Masters of Longevity
On April 8, the streets of Madrid were not the scene of an ordinary protest. Citizens, scientists, entrepreneurs, and healthcare professionals gathered for the Longevity March, a global mobilization that connected Madrid simultaneously with major cities such as Brussels, London, Paris, and Berlin in Europe; Caracas, Mexico City, and San Francisco in the Americas; and Abu Dhabi and Tel Aviv in the Middle East, even during the current war in the region. The message was clear and urgent: aging must be treated as a global political and scientific priority.
The gut microbiome has become a scientific and public fascination, with new studies and health claims emerging daily. While diet is often cited as the key factor shaping gut bacteria, research suggests a far more complex picture. With over 200 variables influencing an individual’s microbiome and only a fraction of its variability explained, the idea of a universally “healthy” gut remains elusive. Popular microbiome tests and interventions may not tell the whole story – especially when stool samples only offer a partial snapshot of the vast intestinal ecosystem. This article explores the intricate relationship between diet, microbiome diversity, and health, challenging common assumptions and highlighting the unanswered questions in this rapidly evolving field.
The Swiss healthcare system is frequently cited as one of the most robust, high-quality, and accessible systems in the world. However, a closer examination of its financial architecture reveals a system fundamentally misaligned with the emerging paradigm of longevity and preventive health. It’s a system optimized for “Sick Care” – the management of acute pathology and established chronic disease – but structurally fails to preserve health capital. This report dissects the structural and economic forces behind this dynamic and explores what would need to change to enable a transition toward a prevention- and longevity-driven healthcare system.
Review finds endothelial aging is driven by accumulating senescent cells and mitochondrial dysfunction, linking mitochondrial decline to increased endothelial senescence and impaired vascular function.
Why it matters The review consolidates mechanistic evidence that mitochondrial decline and endothelial senescence are central drivers of vascular aging and related.
Genflow Biosciences announced international PCT publication WO 2026/062177 A1 covering sirtuin 6 variants for prevention and treatment of muscular diseases, focusing on frailty and sarcopenia.
Why it matters The PCT publication widens Genflow's intellectual property around SIRT6-based interventions and preserves multi-jurisdictional patent options.
Researchers report that the FDA-approved anti-leukemic drug homoharringtonine shows senotherapeutic activity, clearing senescent adipose cells, improving metabolic function, and extending lifespan in mice.
Why it matters Repurposing an already FDA-approved drug could shorten the pathway to clinical testing for senolytic therapies aimed at age- and obesity-related.
A ResearchAndMarkets report profiles more than 80 companies and over 100 RNA therapy candidates, covering coding mRNA and non-coding modalities across development stages and administration routes.
Why it matters The report provides a consolidated view of the global RNA therapeutics landscape, useful for investors, founders, and researchers assessing market.
